Home/Pipeline/BRVT221

BRVT221

Non‑small‑cell lung cancer (I/O)

PreclinicalActive

Key Facts

Indication
Non‑small‑cell lung cancer (I/O)
Phase
Preclinical
Status
Active
Company

About Biorevert

Biorevert uses network‑control systems biology to develop non‑lethal therapies that revert cancer and aging cells to healthy states.

View full company profile

Therapeutic Areas